Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,005,782
  • Shares Outstanding, K 434,152
  • Annual Sales, $ 58,840 K
  • Annual Income, $ -463,660 K
  • EBIT $ -650 M
  • EBITDA $ -613 M
  • 60-Month Beta 0.93
  • Price/Sales 34.09
  • Price/Cash Flow N/A
  • Price/Book 1.92

Options Overview Details

View History
  • Implied Volatility 109.04% ( +5.59%)
  • Historical Volatility 106.70%
  • IV Percentile 68%
  • IV Rank 26.67%
  • IV High 215.16% on 10/15/25
  • IV Low 70.45% on 08/06/25
  • Put/Call Vol Ratio 0.19
  • Today's Volume 13,701
  • Volume Avg (30-Day) 43,691
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 469,226
  • Open Int (30-Day) 477,339

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.42
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +41.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.18 +7.84%
on 11/07/25
7.18 -37.22%
on 10/20/25
-0.81 (-15.27%)
since 10/10/25
3-Month
4.18 +7.84%
on 11/07/25
7.18 -37.22%
on 10/20/25
-0.85 (-15.90%)
since 08/08/25
52-Week
3.79 +18.94%
on 04/09/25
12.36 -63.53%
on 02/18/25
-2.59 (-36.51%)
since 11/08/24

Most Recent Stories

More News
Recursion Pharmaceuticals: Q3 Earnings Snapshot

Recursion Pharmaceuticals: Q3 Earnings Snapshot

RXRX : 4.55 (-1.52%)
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological...

RXRX : 4.55 (-1.52%)
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board...

RXRX : 4.55 (-1.52%)
Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in...

RXRX : 4.55 (-1.52%)
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business...

RXRX : 4.55 (-1.52%)
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk

Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?

MRK : 85.82 (-0.53%)
ABSI : 3.37 (+0.90%)
RXRX : 4.55 (-1.52%)
Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce

While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.

LLY : 969.63 (+4.90%)
RXRX : 4.55 (-1.52%)
PFE : 24.03 (-1.64%)
I Asked ChatGPT’s Most Advanced Model to Find the Stocks Most Likely to 100x Over the Next 10 Years — Here’s What It Said

Here are the stocks that ChatGPT's most advanced model says are most likely to 100x over the next 10 years.

NVDA : 196.40 (+4.38%)
SLDP : 7.62 (+11.08%)
AI : 15.61 (+0.58%)
RKLB : 52.36 (+1.39%)
RXRX : 4.55 (-1.52%)
IONQ : 56.56 (-4.57%)
NNDM : 1.6050 (+5.59%)
ASTS : 69.06 (-0.19%)
ORGN : 0.5539 (+3.90%)
ARQQ : 33.20 (-1.89%)
AEHR : 24.74 (+1.06%)
ABCL : 3.85 (-1.53%)
Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in...

RXRX : 4.55 (-1.52%)
AI Healthcare Tech Revolution Drives $22 Billion Surge as Automation Transforms Medicine

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Healthcare AI technology platforms are experiencing unprecedented adoption as diagnostic markets surge...

ONMD : 1.6450 (+11.15%)
AVAI : 0.3799 (+7.38%)
BTAI : 1.8750 (+2.46%)
CHYM : 21.10 (+3.74%)
ORCL : 242.00 (+1.15%)
RXRX : 4.55 (-1.52%)
WDAY : 225.30 (+0.06%)
PFE : 24.03 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 5.24
2nd Resistance Point 4.94
1st Resistance Point 4.78
Last Price 4.55
1st Support Level 4.32
2nd Support Level 4.02
3rd Support Level 3.86

See More

52-Week High 12.36
Fibonacci 61.8% 9.09
Fibonacci 50% 8.07
Fibonacci 38.2% 7.06
Last Price 4.55
52-Week Low 3.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar